Faraz Zandiyeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Faraz Zandiyeh has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Elahe Zaremoghadam
Department of Internal Medicine, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran
3 shared publications - Farshad Gharebakhshi
Department of Radiology, Imam Hossein Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 shared publications - Abdul Amir H. Kadhum
College of Medicine, University of Al-Ameed, Karbala, Iraq
1 shared publication - Afsaneh Mirshekari
Department of Gastroenterology and Hepatology, School of Medicine, Amir al Momenin Hospital, Zabol University of Medical Science, Zabol, Iran
1 shared publication Aida Rabiei Nezhad
Department of Clinical Toxicology, Toxicological Research Center, Excellence Center of Clinical Toxicology, Loghman Hakim Hospital Shahid Beheshti University of Medical Sciences Tehran Iran
1 shared publication- Ali Rahnama Sisakht
General Medicine, School of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
1 shared publication
Latest Publications
- Open Access
- 21 September 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (9) , e73512
Hemoperfusion as Adjunctive Therapy in Severe Snake Envenomation Refractory to Antivenom: A Case Series
Snake envenomation remains a significant cause of morbidity worldwide, with antivenom serving as the cornerstone of treatment. This case series describes outcomes of three male patients (ages 34–63 years) with severe envenomation who demonstrated progressive local swelling and coagulopathy despite receiving at least 15 vials of antivenom. All received adjunctive hemoperfusion using a Nipro HA230 cartridge via femoral venous access (six two‐hour sessions over three days). All patients survived and were discharged after 4–5 days with normalized coagulation parameters and resolved swelling. No hemoperfusion‐related complications were documented. Total antivenom ranged from 15 to 25 vials. These findings suggest hemoperfusion may be a feasible adjunctive therapy in refractory cases, though the observational design precludes definitive conclusions. Hemoperfusion should be considered experimental, reserved for severe refractory cases in well‐resourced settings.
- 21 September 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (9) , e73512
Open AccessHemoperfusion as Adjunctive Therapy in Severe Snake Envenomation Refractory to Antivenom: A Case Series
Snake envenomation remains a significant cause of morbidity worldwide, with antivenom serving as the cornerstone of treatment. This case series describes outcomes of three male patients (ages 34–63 years) with severe envenomation who demonstrated progressive local swelling and coagulopathy despite receiving at least 15 vials of antivenom. All received adjunctive hemoperfusion using a Nipro HA230 cartridge via femoral venous access (six two‐hour sessions over three days). All patients survived and were discharged after 4–5 days with normalized coagulation parameters and resolved swelling. No hemoperfusion‐related complications were documented. Total antivenom ranged from 15 to 25 vials. These findings suggest hemoperfusion may be a feasible adjunctive therapy in refractory cases, though the observational design precludes definitive conclusions. Hemoperfusion should be considered experimental, reserved for severe refractory cases in well‐resourced settings.
- Open Access
- 7 December 2024
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 11 (2) , e40680
Relationship between gallstone and biliary tract neoplasm; a systematic review and meta-analysis of cohort and case-control studies
Introduction: As a common disease, gallstone has the potential to increase the risk of biliary tract neoplasm via inflammation, bile flow alterations, or changing the levels of metabolic hormones. Objectives: The present systematic review intended to investigate the potential relationship between gallstone and biliary tract neoplasm. Materials and Methods: The present study was conducted through a systematic review and meta-analysis, based on the guidelines provided by PRISMA. A comprehensive search was performed in the Web of Science, Cochrane, ProQuest, PubMed, and Google Scholar databases until February 20, 2024. Moreover, data analysis was performed using the STATA 14 software, and the significance level was set at P<0.05. Results: The present systematic review included 14 case-control and 11 cohort studies. According to our results, gallstone increased the risk of biliary tract neoplasm in all studies (OR: 4.08, 95% CI: 2.82, 5.92), including cohort (OR: 4.35, 95% CI: 2.61, 7) and case-control studies (OR: 3.87, 95% CI: 2.22, 6.72). Moreover, the increased risk of biliary tract neoplasm was reported in the gallstone patients of the age groups of 40-49 years (OR: 2.97, 95% CI: 2.30, 3.84), 50-59 years (OR: 2.92, 95% CI: 2.02, 4.23), and 60-69 years (OR: 6.34, 95% CI: 4, 10.07). Furthermore, the patients with gallstones were at an increased risk of gallbladder cancer (OR: 6.24, 95% CI: 3.95, 9.85), intrahepatic bile duct cancer (OR: 4.46, 95% CI: 1.31, 15.15), extrahepatic bile duct cancer (OR: 4.19, 95), and ampulla of Vater cancer (OR: 2.47, 95% CI: 1.53, 3.99) compared to patients without gallstones. Conclusion: Gallstones significantly increased the risk of biliary tract neoplasm, with the highest risk reported in the age group of 60-69 years. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42024518046) and Research Registry (UIN: reviewregistry1800) website.
- 7 December 2024
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
- Vol. 11 (2) , e40680
Open AccessRelationship between gallstone and biliary tract neoplasm; a systematic review and meta-analysis of cohort and case-control studies
Introduction: As a common disease, gallstone has the potential to increase the risk of biliary tract neoplasm via inflammation, bile flow alterations, or changing the levels of metabolic hormones. Objectives: The present systematic review intended to investigate the potential relationship between gallstone and biliary tract neoplasm. Materials and Methods: The present study was conducted through a systematic review and meta-analysis, based on the guidelines provided by PRISMA. A comprehensive search was performed in the Web of Science, Cochrane, ProQuest, PubMed, and Google Scholar databases until February 20, 2024. Moreover, data analysis was performed using the STATA 14 software, and the significance level was set at P<0.05. Results: The present systematic review included 14 case-control and 11 cohort studies. According to our results, gallstone increased the risk of biliary tract neoplasm in all studies (OR: 4.08, 95% CI: 2.82, 5.92), including cohort (OR: 4.35, 95% CI: 2.61, 7) and case-control studies (OR: 3.87, 95% CI: 2.22, 6.72). Moreover, the increased risk of biliary tract neoplasm was reported in the gallstone patients of the age groups of 40-49 years (OR: 2.97, 95% CI: 2.30, 3.84), 50-59 years (OR: 2.92, 95% CI: 2.02, 4.23), and 60-69 years (OR: 6.34, 95% CI: 4, 10.07). Furthermore, the patients with gallstones were at an increased risk of gallbladder cancer (OR: 6.24, 95% CI: 3.95, 9.85), intrahepatic bile duct cancer (OR: 4.46, 95% CI: 1.31, 15.15), extrahepatic bile duct cancer (OR: 4.19, 95), and ampulla of Vater cancer (OR: 2.47, 95% CI: 1.53, 3.99) compared to patients without gallstones. Conclusion: Gallstones significantly increased the risk of biliary tract neoplasm, with the highest risk reported in the age group of 60-69 years. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42024518046) and Research Registry (UIN: reviewregistry1800) website.
- Open Access
- 1 January 2024
- Published by Maad Rayan Publishing Company in Journal of Renal Endocrinology
- Vol. 10 (1) , e25133
Vitamin D and its role in health; A review of mechanisms, risk factors, sources, and health benefits
Vitamin D is crucial for maintaining optimal health. This review study evaluates health problems related to deficiency and ways to maintain sufficient levels. We conducted a review of the association between vitamin D inadequacy and various diseases, explored the various sources of vitamin D and the risk factors associated with vitamin D insufficiency, examined the consequences of insufficient vitamin D levels, and assessed the potential benefits of taking vitamin D supplements for promoting good health. A literature review demonstrated that maintaining sufficient levels of vitamin D is essential for improving health and preventing various diseases. Vitamin D deficiency is a common condition, and it can be addressed by consuming a balanced diet, getting regular exposure to sunlight, or taking supplements as necessary.
- 1 January 2024
- Published by Maad Rayan Publishing Company in Journal of Renal Endocrinology
- Vol. 10 (1) , e25133
Open AccessVitamin D and its role in health; A review of mechanisms, risk factors, sources, and health benefits
Vitamin D is crucial for maintaining optimal health. This review study evaluates health problems related to deficiency and ways to maintain sufficient levels. We conducted a review of the association between vitamin D inadequacy and various diseases, explored the various sources of vitamin D and the risk factors associated with vitamin D insufficiency, examined the consequences of insufficient vitamin D levels, and assessed the potential benefits of taking vitamin D supplements for promoting good health. A literature review demonstrated that maintaining sufficient levels of vitamin D is essential for improving health and preventing various diseases. Vitamin D deficiency is a common condition, and it can be addressed by consuming a balanced diet, getting regular exposure to sunlight, or taking supplements as necessary.
- Open Access
- 29 July 2023
- Published by Maad Rayan Publishing Company in Journal of Nephropathology
Dapagliflozin in patients with chronic kidney disease: a systematic review and meta-analysis on randomized, double-blind, placebo-controlled multicenter trials
Introduction: Sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce the mortality rate, hospitalization, and cardiac morbidity in diabetic patients. However, their safety in chronic kidney disease (CKD) individuals is still debatable. Objectives: The present study aims to evaluate the effect of dapagliflozin on primary composite outcomes and mortality rate in CKD patients using a systematic review and meta-analysis approach. Materials and Methods: In this meta-analysis, Cochrane, Web of Science, Scopus, and PubMed databases, along with the Google Scholar search engine, were queried until March 2023. Data were analyzed by STATA software version 14 at a significance level of P<0.05. Results: A total of nine randomized clinical trials (RCTs) articles were reviewed, with a sample size of 16720 in the dapagliflozin group and 13 476 in the placebo group. Dapagliflozin use (10 mg/d) compared to placebo improved primary composite outcomes in CKD patients by 39% (OR=0.61, 95% CI: 0.57, 0.65) while reducing the mortality rate by 31% (OR=0.69, 95% CI: 0.63, 0.76). In an analysis by treatment length, no statistically significant change was noted in early composite outcomes (OR=0.70, 95% CI: 0.48, 1.01) and mortality rate (OR=0.75, 95% CI: 0.39, 1.45) between patients who were on dapagliflozin for less than two years and the placebo group. However, patients receiving dapagliflozin for two years and above had significantly improved primary composite outcomes (OR=0.60, 95% CI: 0.55, 0.66) and mortality rate (OR=0.69, 95% CI: 0.61, 0.79) compared to the placebo group. Conclusion: Dapagliflozin use, compared to placebo, improved the early composite outcomes and mortality rate in CKD patients. Prescribing a daily dose of 10 mg for a treatment duration of over two years seems safe in these patients. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (ID: CRD42023422186).
- 29 July 2023
- Published by Maad Rayan Publishing Company in Journal of Nephropathology
Open AccessDapagliflozin in patients with chronic kidney disease: a systematic review and meta-analysis on randomized, double-blind, placebo-controlled multicenter trials
Introduction: Sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce the mortality rate, hospitalization, and cardiac morbidity in diabetic patients. However, their safety in chronic kidney disease (CKD) individuals is still debatable. Objectives: The present study aims to evaluate the effect of dapagliflozin on primary composite outcomes and mortality rate in CKD patients using a systematic review and meta-analysis approach. Materials and Methods: In this meta-analysis, Cochrane, Web of Science, Scopus, and PubMed databases, along with the Google Scholar search engine, were queried until March 2023. Data were analyzed by STATA software version 14 at a significance level of P<0.05. Results: A total of nine randomized clinical trials (RCTs) articles were reviewed, with a sample size of 16720 in the dapagliflozin group and 13 476 in the placebo group. Dapagliflozin use (10 mg/d) compared to placebo improved primary composite outcomes in CKD patients by 39% (OR=0.61, 95% CI: 0.57, 0.65) while reducing the mortality rate by 31% (OR=0.69, 95% CI: 0.63, 0.76). In an analysis by treatment length, no statistically significant change was noted in early composite outcomes (OR=0.70, 95% CI: 0.48, 1.01) and mortality rate (OR=0.75, 95% CI: 0.39, 1.45) between patients who were on dapagliflozin for less than two years and the placebo group. However, patients receiving dapagliflozin for two years and above had significantly improved primary composite outcomes (OR=0.60, 95% CI: 0.55, 0.66) and mortality rate (OR=0.69, 95% CI: 0.61, 0.79) compared to the placebo group. Conclusion: Dapagliflozin use, compared to placebo, improved the early composite outcomes and mortality rate in CKD patients. Prescribing a daily dose of 10 mg for a treatment duration of over two years seems safe in these patients. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (ID: CRD42023422186).
- Open Access
- 29 July 2023
- Published by Maad Rayan Publishing Company in Journal of Parathyroid Disease
- Vol. 11 (1) , e11211
Association of parathyroid hormone with plasma magnesium in health and disease; a review
Parathyroid hormone (PTH) is a hormone produced by the parathyroid glands that regulates calcium and phosphate metabolism in the body. Magnesium is an essential mineral that plays a role in many cellular processes, including nerve and muscle function, DNA synthesis, and bone health. This review aims to examine the association between PTH and magnesium in health and disease states. Several studies have shown that lower levels of magnesium in the blood are associated with higher levels of PTH. This association has been observed in both healthy individuals and those with chronic kidney disease, primary hyperparathyroidism, and vitamin D deficiency. The mechanism by which magnesium regulates PTH synthesis is not yet fully understood but appears to involve magnesium’s role in the calcium-sensing receptor (CaSR) and cellular signaling pathways. In conclusion, the evidence suggests a clear and significant association between PTH and magnesium, with lower serum magnesium levels associated with elevated PTH levels. Further research is needed to understand clinical practice’s underlying mechanisms and implications.
- 29 July 2023
- Published by Maad Rayan Publishing Company in Journal of Parathyroid Disease
- Vol. 11 (1) , e11211
Open AccessAssociation of parathyroid hormone with plasma magnesium in health and disease; a review
Parathyroid hormone (PTH) is a hormone produced by the parathyroid glands that regulates calcium and phosphate metabolism in the body. Magnesium is an essential mineral that plays a role in many cellular processes, including nerve and muscle function, DNA synthesis, and bone health. This review aims to examine the association between PTH and magnesium in health and disease states. Several studies have shown that lower levels of magnesium in the blood are associated with higher levels of PTH. This association has been observed in both healthy individuals and those with chronic kidney disease, primary hyperparathyroidism, and vitamin D deficiency. The mechanism by which magnesium regulates PTH synthesis is not yet fully understood but appears to involve magnesium’s role in the calcium-sensing receptor (CaSR) and cellular signaling pathways. In conclusion, the evidence suggests a clear and significant association between PTH and magnesium, with lower serum magnesium levels associated with elevated PTH levels. Further research is needed to understand clinical practice’s underlying mechanisms and implications.
- Open Access
- 10 April 2023
- Published by Maad Rayan Publishing Company in Journal of Nephropathology
The effects of atorvastatin on contrast-induced acute kidney injury; a systematic review and meta-analysis on clinical trials
Introduction: Contrast-induced acute kidney injury (CI-AKI) is a major acute renal failure that can be prevented by atorvastatin administration. This study aims to evaluate the association between atorvastatin use and CI-AKI incidence using a systematic review and meta-analysis approach. Materials and Methods: Several international databases, including Cochrane, Web of Science, Scopus, ProQuest, PubMed, and the Google Scholar search engine, were queried in this study. STATA 14 software was conducted to analyze the data. In this study, standardized mean difference (SMD) index was conducted to investigate the relationship between atorvastatin and serum creatinine level. Results: Twelve clinical trials with a total sample size of 3299 were retrieved. The effect of atorvastatin on serum creatinine levels indicated a SMD of -2.26 (95% CI: -2.53, -1.98) at a dose of 20 mg/kg, -0.76 (95% CI: -1.47, -0.05) at a dose of 40 mg/kg, -2.69 (95% CI: -2.96, -2.42) at a dose of 60 mg/ kg, and -0.03 (95% CI: -0.14, 0.09) at a dose of 80 mg/kg. The effect of atorvastatin use on serum creatinine levels achieved a SMD of -2.72 (95% CI: -3.02, -2.43) in the 40-49 years age group and a SMD of -0.96 (95% CI: -1.73, -0.19) in the 50-59 years age group. The effect of high-dose atorvastatin therapy in reducing the serum creatinine levels, compared to low-dose therapy, was a SMD of -0.54 (95% CI: -1.03, -0.04). However, estimates for the effect of atorvastatin compared to rosuvastatin and placebo showed a SMD of -0.26 (95% CI: -0.76, 0.24) and -1.23 (95% CI: -2.22, -0.25), respectively. The effect of atorvastatin on blood urea nitrogen (BUN) and high-sensitivity C-reactive protein (hs-CRP) levels relative to the comparison group was a SMD of -1.10 (95% CI: -1.61, -0.58) and -1.36 (95% CI: -2.30, -0.42) respectively. Conclusion: Pre-treatment with atorvastatin is effective in CI-AKI prevention. High-dose atorvastatin administration at younger ages provides the best outcome for preventing CI-AKI. Meta-analysis Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (ID: CRD42023397276, available at https:// www.crd.york.ac.uk/prospero/#recordDetails).
- 10 April 2023
- Published by Maad Rayan Publishing Company in Journal of Nephropathology
Open AccessThe effects of atorvastatin on contrast-induced acute kidney injury; a systematic review and meta-analysis on clinical trials
Introduction: Contrast-induced acute kidney injury (CI-AKI) is a major acute renal failure that can be prevented by atorvastatin administration. This study aims to evaluate the association between atorvastatin use and CI-AKI incidence using a systematic review and meta-analysis approach. Materials and Methods: Several international databases, including Cochrane, Web of Science, Scopus, ProQuest, PubMed, and the Google Scholar search engine, were queried in this study. STATA 14 software was conducted to analyze the data. In this study, standardized mean difference (SMD) index was conducted to investigate the relationship between atorvastatin and serum creatinine level. Results: Twelve clinical trials with a total sample size of 3299 were retrieved. The effect of atorvastatin on serum creatinine levels indicated a SMD of -2.26 (95% CI: -2.53, -1.98) at a dose of 20 mg/kg, -0.76 (95% CI: -1.47, -0.05) at a dose of 40 mg/kg, -2.69 (95% CI: -2.96, -2.42) at a dose of 60 mg/ kg, and -0.03 (95% CI: -0.14, 0.09) at a dose of 80 mg/kg. The effect of atorvastatin use on serum creatinine levels achieved a SMD of -2.72 (95% CI: -3.02, -2.43) in the 40-49 years age group and a SMD of -0.96 (95% CI: -1.73, -0.19) in the 50-59 years age group. The effect of high-dose atorvastatin therapy in reducing the serum creatinine levels, compared to low-dose therapy, was a SMD of -0.54 (95% CI: -1.03, -0.04). However, estimates for the effect of atorvastatin compared to rosuvastatin and placebo showed a SMD of -0.26 (95% CI: -0.76, 0.24) and -1.23 (95% CI: -2.22, -0.25), respectively. The effect of atorvastatin on blood urea nitrogen (BUN) and high-sensitivity C-reactive protein (hs-CRP) levels relative to the comparison group was a SMD of -1.10 (95% CI: -1.61, -0.58) and -1.36 (95% CI: -2.30, -0.42) respectively. Conclusion: Pre-treatment with atorvastatin is effective in CI-AKI prevention. High-dose atorvastatin administration at younger ages provides the best outcome for preventing CI-AKI. Meta-analysis Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO website (ID: CRD42023397276, available at https:// www.crd.york.ac.uk/prospero/#recordDetails).
- Open Access
- 27 January 2023
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
Pulmonary radiologic findings based on Warrick score as a predictor of COVID-19 patients’ outcomes
Introduction: Predicting factors related to the severity and mortality of coronavirus disease 2019 (COVID-19) patients can significantly help in better management of their treatment. Objectives: This study aimed to investigate the correlation between pulmonary radiologic findings based on the Warrick score and COVID-19 patients’ outcomes. Patients and Methods: This descriptive-analytical study was conducted on 436 COVID-19 patients hospitalized at Shahid Mohammadi hospital in Bandar Abbas. Pulmonary radiologic findings were scored based on the Warrick score. Outcomes of COVID-19 patients, including disease severity and mortality, were followed. Independent T-test and binary logistic regression were conducted to explore the correlation between the pulmonary radiologic findings and patients’ outcomes. Results: Results showed that the correlation between pulmonary radiologic findings with both disease severity and mortality was significant, since higher pulmonary involvement caused greater severity and mortality. The Warrick score difference between dead and recovered patients and low and high disease severity were significant, therefore greater Warrick score caused more disease severity and mortality. Conclusion: Pulmonary radiologic findings based on the Warrick score can use as a predictor of COVID-19 patients’ outcomes.
- 27 January 2023
- Published by Maad Rayan Publishing Company in Immunopathologia Persa
Open AccessPulmonary radiologic findings based on Warrick score as a predictor of COVID-19 patients’ outcomes
Introduction: Predicting factors related to the severity and mortality of coronavirus disease 2019 (COVID-19) patients can significantly help in better management of their treatment. Objectives: This study aimed to investigate the correlation between pulmonary radiologic findings based on the Warrick score and COVID-19 patients’ outcomes. Patients and Methods: This descriptive-analytical study was conducted on 436 COVID-19 patients hospitalized at Shahid Mohammadi hospital in Bandar Abbas. Pulmonary radiologic findings were scored based on the Warrick score. Outcomes of COVID-19 patients, including disease severity and mortality, were followed. Independent T-test and binary logistic regression were conducted to explore the correlation between the pulmonary radiologic findings and patients’ outcomes. Results: Results showed that the correlation between pulmonary radiologic findings with both disease severity and mortality was significant, since higher pulmonary involvement caused greater severity and mortality. The Warrick score difference between dead and recovered patients and low and high disease severity were significant, therefore greater Warrick score caused more disease severity and mortality. Conclusion: Pulmonary radiologic findings based on the Warrick score can use as a predictor of COVID-19 patients’ outcomes.